Login / Signup

The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.

Ellen BurgessStefan D AnkerGerasimos FilippatosBertram PittLuis M RuilopeLiana K BillingsJennifer B GreenDaisuke KoyaLawrence A LeiterKevin M PantaloneChristiane AhlersAndrea LageRobert LawatscheckAndrea ScaliseGeorge L Bakris
Published in: Diabetes, obesity & metabolism (2023)
In FIDELITY, benefits of finerenone in lowering the risk of cardiovascular and kidney outcomes were not significantly modified by patient obesity.
Keyphrases
  • type diabetes
  • insulin resistance
  • metabolic syndrome
  • weight loss
  • glycemic control
  • high fat diet induced
  • weight gain
  • cardiovascular disease
  • adipose tissue
  • physical activity